---
stepsCompleted:
  - step-01-document-discovery
  - step-02-prd-analysis
  - step-03-epic-coverage-validation
  - step-04-ux-alignment
  - step-05-epic-quality-review
  - step-06-final-assessment
documentInventoryConfirmed: true
---

# Implementation Readiness Assessment Report

**Date:** 2026-04-06
**Project:** pharma_RD_workflow

## Document Discovery (Step 1)

*Confirmed via user **[C] Continue** on 2026-04-06.*

### PRD documents

**Whole documents:**

| File | Size | Modified |
|------|------|----------|
| `prd.md` | 29,239 bytes | 2026-04-04 |

**Sharded documents:** none found (`*prd*/index.md` not present)

### Architecture documents

**Whole documents:**

| File | Size | Modified |
|------|------|----------|
| `architecture.md` | 23,341 bytes | 2026-04-04 |

**Sharded documents:** none found

### Epics & stories documents

**Whole documents:**

| File | Size | Modified |
|------|------|----------|
| `epics.md` | 33,711 bytes | 2026-04-05 |

**Sharded documents:** none found

### UX design documents

**Whole documents:** none matching `*ux*.md`

**Sharded documents:** none found

### Critical issues

- **Duplicates:** No duplicate whole + sharded pairs detected for PRD, architecture, or epics.
- **Missing (warning):** No UX design document (`*ux*.md` or `*ux*/index.md`) under planning artifacts. Assessment can proceed, but UX coverage will be noted as absent unless located elsewhere.

---

## PRD Analysis (Step 2)

**Source:** `prd.md` (whole document; read in full).

### Functional Requirements

| ID | Requirement text |
|----|------------------|
| **FR1** | Workflow operator can start a full **pipeline run** on demand. |
| **FR2** | Workflow operator can configure a **recurring schedule** for pipeline runs (default: weekly). |
| **FR3** | System can execute agent stages in the **required order** with defined **handoffs** between stages. |
| **FR4** | System can **persist** intermediate outputs between stages for a given run identifier. |
| **FR5** | System can associate all stage outputs with a **single run** (correlation) for traceability and demo. |
| **FR6** | Clinical Data Agent can **discover and summarize** new or updated **clinical trial publications** relevant to configured therapeutic areas. |
| **FR7** | Clinical Data Agent can ingest **internal research summaries** when supplied via configured inputs (including **stub/sample** data for practice). |
| **FR8** | Competitor Intelligence Agent can track **competitor product approvals** and material **regulatory disclosures** for configured competitors. |
| **FR9** | Competitor Intelligence Agent can track **pipeline disclosures** relevant to configured watch scopes. |
| **FR10** | Competitor Intelligence Agent can **flag** significant **patent filing** activity for configured competitors. |
| **FR11** | Consumer Insight Agent can process **consumer feedback** signals from configured sources (public/mock as scoped). |
| **FR12** | Consumer Insight Agent can incorporate **pharmacy sales trend** signals when those feeds are configured and available. |
| **FR13** | Consumer Insight Agent can surface **unmet need / demand** signals from configured market sources. |
| **FR14** | Synthesis Agent can **consume** the structured outputs of the Clinical, Competitor, and Consumer agents for a run. |
| **FR15** | Synthesis Agent can **cross-reference** signals across domains to produce a **ranked list** of formulation or line-extension **opportunities**. |
| **FR16** | For each ranked item, Synthesis Agent can attach **supporting evidence** references suitable for **human verification**. |
| **FR17** | For each ranked item, Synthesis Agent can provide a **commercial viability** assessment section (qualitative in MVP unless otherwise specified). |
| **FR18** | Delivery Agent can **render** a **structured insight report** for a completed run. |
| **FR19** | Delivery Agent can **distribute** the report to configured **R&D scientist** and **marketing lead** recipients (channel: email, file drop, or in-app viewer—implementation open). |
| **FR20** | R&D scientist can **open and read** the structured insight report for a given run. |
| **FR21** | Marketing lead can **open and read** the same structured insight report for a given run. |
| **FR22** | Report presentation can make clear that items are **recommendations** and that **pursuit decisions** remain **human-owned**. |
| **FR23** | Workflow operator can configure **therapeutic area scope** and boundaries for monitoring. |
| **FR24** | Workflow operator can configure **competitor watchlists** and related keywords or identifiers. |
| **FR25** | Workflow operator can configure **connection settings** for external data sources permitted in the deployment (public APIs, files, stubs). |
| **FR26** | System can operate in a **practice** mode using **public and/or mock** sources without requiring enterprise SSO. |
| **FR27** | Structured report can state when **little net-new signal** was found versus material changes. |
| **FR28** | Structured report can summarize **what was scanned** (sources/scopes) for the run at a high level. |
| **FR29** | Workflow operator can view **per-agent status** for an execution. |
| **FR30** | Workflow operator can **retry** a failed stage when supported without manually re-creating upstream artifacts. |
| **FR31** | System can emit **run history** and logs sufficient to produce a **demonstration recording** of agent execution and final delivery. |
| **FR32** | Organization can **restrict access** to reports to **authorized** users or distribution lists (exact mechanism implementation-open; may be coarse in practice builds). |
| **FR33** | *(Phase 2)* System can **alert** stakeholders to major external events between scheduled runs. |
| **FR34** | *(Phase 2)* Admin can integrate **enterprise SSO** and centralized **secrets** management for connectors. |
| **FR35** | *(Phase 3)* System can support **enterprise** audit, PHI-aware feeds, and **multi-tenant** isolation where productized. |

**Total FRs (labeled in PRD):** 35 — **FR1–FR32** MVP contract; **FR33–FR35** explicitly phased post-MVP.

### Non-Functional Requirements

| ID | Requirement text |
|----|------------------|
| **NFR-P1** | A full scheduled pipeline run (all five stages through delivery) completes within a **predictable window** suitable for a **recorded demo** (target: **under 60 minutes wall-clock** for MVP configuration on practice data; configurable timeout per stage). |
| **NFR-P2** | Recipients can open and read a delivered report on typical corporate hardware without **specialized** client software (browser or standard email/PDF—implementation open). |
| **NFR-P3** | External source calls use **timeouts** and **bounded retries** so one slow feed does not block the entire run indefinitely without operator visibility. |
| **NFR-S1** | Secrets (API keys, tokens) are **not** stored in source control; they are injected via **environment** or **secrets** mechanism appropriate to deployment. |
| **NFR-S2** | Report artifacts and logs are **access-controlled** to authorized roles/distribution lists (see FR32). |
| **NFR-S3** | Data in transit between components and external APIs uses **TLS** where APIs support it. |
| **NFR-S4** | MVP assumes **no PHI** in prompts/logs; if PHI is later in scope, processing must follow an **approved** privacy design (out of MVP—see Domain Requirements). |
| **NFR-R1** | Failed stages are **visible** to the workflow operator with **actionable** error summaries (not silent failure). |
| **NFR-R2** | Run history is **durable** enough to answer “what ran, when, and what failed” for **demo** and **debug** (minimum retention: configurable; default **30 days** for practice unless otherwise set). |
| **NFR-R3** | Idempotent or safe **retry** semantics for stage reruns where FR30 applies (no duplicate conflicting artifacts without clear versioning). |
| **NFR-I1** | Connectors declare **expected** data formats and **degrade gracefully** when a source returns empty or partial data (report still generated with transparency per FR27–FR28). |
| **NFR-I2** | Integration failures are **classified** (auth, rate limit, schema change, network) in logs to shorten operator time-to-fix. |
| **NFR-O1** | Each run emits a **correlation identifier** propagated across stages (aligns with FR5). |
| **NFR-O2** | Structured logs contain **stage name**, **start/end**, and **outcome** suitable for **Loom**-style narration. |

**Total NFRs (labeled in PRD):** 14 (P1–P3, S1–S4, R1–R3, I1–I2, O1–O2).

### Additional requirements & constraints (from PRD)

- **Domain-specific:** Decision-support (not SaMD) positioning; human oversight; HIPAA/PHI future; evidence traceability; enterprise security/audit/model governance noted for later.
- **SaaS B2B:** Orchestration-first, versioned agent contracts, single-tenant MVP; RBAC table (R&D, marketing, operator, admin); practice vs enterprise tiers.
- **Scoping:** Growth/Vision features called out separately from MVP; vertical slice strategy.
- **Traceability:** Inputs from product brief and brainstorming session documented in PRD.

### PRD completeness assessment (initial)

- Functional and non-functional requirements are **explicitly numbered** and written as **testable capabilities** where stated.
- **MVP vs phased** work is distinguished (FR33–35, NFR-S4 enterprise note).
- Document is **suitable** for epic/story coverage validation in the next step.

---

## Epic coverage validation (Step 3)

**Source:** `epics.md` — Requirements Inventory + **FR Coverage Map** (lines 102–122) and per-epic **FRs covered** sections.

### Epic FR coverage extracted (from `epics.md`)

| FR range | Epic(s) | Notes in source |
|----------|---------|-----------------|
| FR1 | Epic 1 | On-demand run |
| FR2 | Epic 2 | Schedule |
| FR3–FR5 | Epic 1 | Order, persist, correlation |
| FR6–FR7 | Epic 3 | Clinical |
| FR8–FR10 | Epic 4 | Competitor |
| FR11–FR13 | Epic 5 | Consumer |
| FR14–FR17, FR27–FR28 | Epic 6 | Synthesis + transparency |
| FR18–FR22 | Epic 7 | Delivery & consumption |
| FR23–FR26, FR32 | Epic 8 | Config, practice, access |
| FR29 | Epic 1 (+ Epic 2 for failure states) | Per-agent status |
| FR30 | Epic 2 | Stage retry |
| FR31 | Epic 1, 7 | History + delivery proof |
| FR33–FR35 | — | **Roadmap / out of MVP** |

### FR coverage analysis (MVP contract FR1–FR32)

| FR | Epic assignment | Status |
|----|-----------------|--------|
| FR1–FR32 | As mapped above | **Covered** in epics (see Final validation in `epics.md`) |
| FR33–FR35 | Not in MVP stories | **Intentional** — roadmap only |

### Missing FR coverage

**None** for **FR1–FR32**. The epics document explicitly lists FR33–FR35 as post-MVP; that matches the PRD phasing.

### Coverage statistics

| Metric | Value |
|--------|------:|
| PRD FRs (total labeled) | 35 |
| MVP FRs (FR1–FR32) | 32 |
| MVP FRs mapped to epics | 32 |
| MVP coverage | **100%** |
| Post-MVP FRs (FR33–35) | 3 (excluded from MVP contract by design) |

---

## UX alignment assessment (Step 4)

### UX document status

**Not found** under `_bmad-output/planning-artifacts/` — no `*ux*.md` or `*ux*/index.md`.

`epics.md` states (lines 98–100): *No UX design specification document was present under `planning-artifacts`. Report consumption may use **email**, **file drop**, or a **minimal static viewer** per PRD—captured under Epic 7 stories.*

### Alignment issues

- No separate UX artifact to cross-check against PRD journeys or architecture **visual** layer.
- PRD and epics already constrain **report structure**, **readability** (NFR-P2), and **human-owned** language (FR22); these are covered by stories, not by a UX spec.

### Warnings

- **Low severity for this product:** PRD classifies the product as **CLI / workflow / artifacts**-first; **mobile-first UI is out of scope** unless added later. Missing a dedicated UX doc is a **process gap**, not an automatic blocker if stakeholders accept **Epic 7** stories as the consumption UX contract.
- If future work adds a **web app** or rich operator UI, add a **`bmad-create-ux-design`** (or equivalent) artifact before implementation.

---

## Epic quality review (Step 5)

**Source:** `epics.md` — epic goals, story list, dependency notes, Final validation.

### User value focus

- Epics are framed around **operators**, **scientists**, **marketing**, **admins** — not raw technical milestones only. Epic 1’s first story is architecture baseline (greenfield expectation); subsequent stories deliver **persistence**, **pipeline**, **logging**, **CLI trigger**, **status** — each tied to operator/demo outcomes.

### Epic independence

- Documented order: Epic 1 backbone; Epic 2 scheduling/resilience; Epics 3–5 parallelizable agents after contracts; Epic 6 synthesis; Epic 7 delivery; Epic 8 config (can start early in parallel). **No epic requires a later epic’s runtime features** beyond standard forward build order.

### Story quality

- Stories use **Given/When/Then** (or equivalent) and reference **FR/NFR** IDs.
- **Final validation** in `epics.md` asserts FR coverage and story sizing; dependency flow is **forward** within epics.

### Findings by severity

| Severity | Finding |
|----------|---------|
| **Critical** | None identified |
| **Major** | None identified |
| **Minor** | No standalone UX spec (see Step 4). Story 1.1 is **setup-heavy** but aligned with architecture **starter template** expectation for greenfield. |

---

## Summary and recommendations (Step 6)

### Overall readiness status

**READY** — for **Phase 4 implementation** as scoped in the PRD (MVP FR1–FR32, supporting NFRs), assuming the team accepts **Epic 7** + PRD journeys as the substitute for a separate UX specification for report consumption.

### Critical issues requiring immediate action

- **None** for FR traceability or epic/story structure at planning-artifact level.

### Recommended next steps

1. **Proceed to implementation** using existing **`bmad-sprint-planning`** / **`bmad-dev-story`** cadence (or continue if already in progress); sprint status shows delivery stories completed — this readiness check validates **planning alignment**, not runtime code.
2. **Optional:** Add a lightweight **UX notes** doc if marketing or compliance asks for explicit screen/report layout sign-off beyond Epic 7 ACs.
3. **When scoping Phase 2:** Re-open **FR33–FR35** and **`bmad-correct-course`** or PRD edit before new epics.

### Final note

This assessment found **no missing MVP FR coverage** in epics and **no critical** epic-quality violations. **One warning:** no dedicated UX design file — acceptable for current CLI/report artifact scope per PRD. Address the optional UX doc if the product grows a significant UI surface.

**Assessor:** BMad workflow `bmad-check-implementation-readiness` (automated run)  
**Report date:** 2026-04-06
